Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 7/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16137332 | 0.88 | LRRK2 (0.47) | SYKAURKALRRK2MAPK3 | |
| SCHEMBL16134079 | 0.83 | PLK1 (0.48) | SYKAURKALRRK2MAPK3MAPKAPK2 | |
| SCHEMBL24690431 | 0.80 | FGFR4 (0.51) | SYKLRRK2MAPK3FGFR4 | |
| SCHEMBL15946708 | 0.77 | CCNK (0.42) | SYKLRRK2MAPK3 | |
| SCHEMBL15948508 | 0.75 | MAPK3 (0.48) | MAPK3ULK1 | |
| SCHEMBL736662 | 0.73 | POLB (0.49) | — | |
| SCHEMBL5424196 | 0.73 | LRRK2 (0.60) | AURKALRRK2HDAC1ULK1 | |
| SCHEMBL2880191 | 0.73 | LMNA (0.54) | — | |
| SCHEMBL29353000 | 0.72 | HDAC1 (0.52) | HDAC1 | |
| SCHEMBL211033 | 0.72 | HDAC1 (0.52) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
| US-10189794-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-01-29 | — | — | US | disclosed |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-01-25 | — | — | US | disclosed |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-01-25 | — | — | US | disclosed |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
| US-9663524-B2 | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors | CELGENE CAR LLC (BM) | 2017-05-30 | — | — | US | disclosed |
| US-9663524-B2 | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors | CELGENE CAR LLC (BM) | 2017-05-30 | — | — | US | disclosed |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-08-04 | — | — | US | disclosed |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-08-04 | — | — | US | disclosed |
| US-9321786-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321786-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-18 | — | — | US | disclosed |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-18 | — | — | US | disclosed |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | SYK 1134/4885AURKA 118/4885LRRK2 358/4885 |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885AURKA 1849/4885LRRK2 1200/4885 |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885AURKA 1849/4885LRRK2 1200/4885 |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | SYK 1134/4885AURKA 118/4885LRRK2 358/4885 |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885AURKA 1849/4885LRRK2 1200/4885 |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | SYK 577/4885AURKA 130/4885LRRK2 978/4885 |
| US-10189794-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885AURKA 1849/4885LRRK2 1200/4885 |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885AURKA 1849/4885LRRK2 1200/4885 |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885AURKA 1849/4885LRRK2 1200/4885 |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | SYK 1134/4885AURKA 118/4885LRRK2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.